Greater Risk of Death in Cancer Patients Who Choose Alternative Therapies

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights a recent study that looked at the survival impact of cancer patients who chose alternative medicine instead of conventional cancer treatments.

In this video, Skyler Johnson, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses a study that looked at the survival impact of cancer patients who chose alternative medicine instead of conventional cancer treatments.

The study was recently published online ahead of print in the Journal of the National Cancer Institute.

Johnson presented the results at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego (abstract 2952).

Related Videos
Byoung Chul Cho, MD, PhD, highlights ongoing trials assessing intravenous and subcutaneous amivantamab in EGFR-mutant non–small cell lung cancer.
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Related Content
Subgroup findings suggest a PFS benefit with the addition of encorafenib/binimetinib in patients with liver metastases.

Encorafenib Regimen Shows No PFS Improvement in Metastatic BRAF+ Melanoma

Chris Ryan
June 1st 2024
Article

Subgroup findings suggest a PFS benefit with the addition of encorafenib/binimetinib in patients with liver metastases.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Brentuximab Vedotin Improves Efficacy in Classical Hodgkin Lymphoma

Brentuximab Vedotin Improves Efficacy in Classical Hodgkin Lymphoma

Brielle Benyon
June 1st 2024
Article

Brentuximab vedotin led to unprecedented progression-free survival for patients with classical Hodgkin lymphoma.

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy

Amy Tiersten, MD
January 1st 2024
Podcast

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

Post-Hoc OPTIC Results Showcase Continued Safety in CP-CML

Post-Hoc OPTIC Results Showcase Continued Safety in CP-CML

Kristi Rosa
June 1st 2024
Article

Ponatinib remains a safe treatment for patients with chronic-phase chronic myeloid leukemia.

Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma

Dabrafenib/Trametinib Yields Sustained Survival During Long-Term Follow-up in Advanced Melanoma

Gina Mauro
June 1st 2024
Article

Continued survival was observed in dabrafenib/trametinib combination after 8 years follow-up in patients with advanced melanoma.